MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

8.79 -5.59

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.76

Max

9.29

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M -20M
Verkäufe	5.9M 40M
Gewinnspanne	-49.569
Angestellte	184
EBITDA	16M -19M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+154.83% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	213M 962M
Vorheriger Eröffnungskurs	14.38
Vorheriger Schlusskurs	8.79

Nachrichtenstimmung

By Acuity

92%

7 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Jan. 2026, 22:45 UTC

Wichtige Markttreiber

GH Research Shares Up, Plans to Provide Update on New Drug Application

2. Jan. 2026, 22:13 UTC

Market Talk

Ergebnisse

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2. Jan. 2026, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

2. Jan. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. Jan. 2026, 21:07 UTC

Ergebnisse

Tesla Stock Pops and Drops After Fourth-Quarter Deliveries. -- Barrons.com

2. Jan. 2026, 20:09 UTC

Market Talk

Oil Futures Slip in First Trading Day of the Year -- Market Talk

2. Jan. 2026, 19:48 UTC

Market Talk

U.S. Natural Gas Futures Kick Off 2026 With A Loss -- Market Talk

2. Jan. 2026, 18:53 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Jan. 2026, 18:53 UTC

Market Talk

Mexico PMIs Show Manufacturing Weakness in December -- Market Talk

2. Jan. 2026, 17:56 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Meta's Manus Acquisition May Help Fill AI Monetization Gap -- Market Talk

2. Jan. 2026, 17:50 UTC

Market Talk

Apparel Industry Seen With Strength Across Income Levels -- Market Talk

2. Jan. 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. Jan. 2026, 16:33 UTC

Market Talk

Remittances to Mexico Fell 5.7% in November -- Market Talk

2. Jan. 2026, 16:18 UTC

Market Talk

Tesla Dethroned as World's Largest EV Maker -- Market Talk

2. Jan. 2026, 15:48 UTC

Ergebnisse

Software Has Been Battered by AI. Shopify, Veeva, and 3 More Stocks to Play a Turnaround. -- Barrons.com

2. Jan. 2026, 15:17 UTC

Market Talk

Tesla Expected to Make Its Switch to Robotics, AI in 2026 -- Market Talk

2. Jan. 2026, 15:01 UTC

Market Talk

Sable Seen Nearing Production Relaunch After Court Ruling -- Market Talk

2. Jan. 2026, 15:00 UTC

Ergebnisse

The Maker of Biscoff Cookies Bets on a Global Expansion -- WSJ

2. Jan. 2026, 14:56 UTC

Market Talk

Tesla's Sales Drop Was Better Than Feared -- Market Talk

2. Jan. 2026, 14:20 UTC

Market Talk

Capstone Copper's Mantoverde Strike Could Be Costly -- Market Talk

2. Jan. 2026, 14:20 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Jan. 2026, 14:13 UTC

Market Talk

Oil Futures Open Year Lower on Oversupply Concerns -- Market Talk

2. Jan. 2026, 13:39 UTC

Market Talk

U.S. Natural Gas Futures Open Year Lower -- Market Talk

2. Jan. 2026, 13:01 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Unicredit Could Buy Delfin's BMPS Stake, Launch Full Takeover, Equita Says -- Market Talk

2. Jan. 2026, 12:45 UTC

Market Talk

Emerging-Market Dollar Bonds Record Strong Returns in 2025 -- Market Talk

2. Jan. 2026, 11:48 UTC

Market Talk

European Gas Climbs as Cold Weather Bites -- Market Talk

2. Jan. 2026, 11:36 UTC

Market Talk

Treasury Yields, Dollar Edge Higher as Near-Term Fed Rate Cut Looks Unlikely -- Market Talk

2. Jan. 2026, 11:30 UTC

Market Talk

Copper Rally Continues, Spurred by Supply Shocks -- Market Talk

2. Jan. 2026, 11:29 UTC

Market Talk

Dollar Rises After Posting Worst Year Since 2017 -- Market Talk

2. Jan. 2026, 11:15 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

154.83% Vorteil

12-Monats-Prognose

Durchschnitt 23.75 USD 154.83%

Hoch 34 USD

Tief 16 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

7 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.